NONSMALL CELL LUNG CANCER
Clinical trials for NONSMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new NONSMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for NONSMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody combo tested for tough cancers
Disease control CompletedThis early-phase study tested a new experimental drug called HMBD-002, alone or with another cancer drug (pembrolizumab), in 48 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see …
Matched conditions: NONSMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Hummingbird Bioscience • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Electric field therapy extends life in advanced lung cancer trial
Disease control CompletedThis phase 3 trial tested a portable device that delivers low-intensity electric fields (TTFields) to the chest in 291 adults with stage 4 non-small cell lung cancer that worsened after initial chemotherapy. Participants received either standard treatments (chemotherapy or immuno…
Matched conditions: NONSMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: NovoCure GmbH • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Immunotherapy shows promise in lung cancer battle
Disease control CompletedThis study tested a new immunotherapy drug, cemiplimab, against standard chemotherapy in 712 people with advanced non-small cell lung cancer that has a specific marker (PD-L1). The goal was to see if cemiplimab helps people live longer or keeps the cancer from growing longer than…
Matched conditions: NONSMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Tiny study tests Gene-Guided radiation for lung cancer
Knowledge-focused CompletedThis very early study looked at whether it's possible to use a patient's tumor genetics to customize radiation doses for stage 2 or 3 non-small cell lung cancer. Only 3 people took part, and the main goal was to see if the approach was safe and doable. The study is complete, but …
Matched conditions: NONSMALL CELL LUNG CANCER
Phase: EARLY_PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated May 08, 2026 12:03 UTC